Abstract
To study the efficacy of moxifloxacin treatment for tuberculosis, we utilized a novel cartridge system to simulate in vivo pharmacokinetics. We found this system to be a robust method for modeling in vivo pharmacokinetics and present data supporting the utility of intermittent moxifloxacin treatment as a component of antituberculosis chemotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 853-856 |
Number of pages | 4 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 49 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2005 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases